Among HER2-amplified adenocarcinomas, 24 (52.2%) and 3 (6.5%) had EGFR and KRAS mutations, respectively, while 1 (2.2%) showed ALK rearrangement. The gene discussed is KRAS; the disease is adenocarcinoma.